

RENAL DENERVATION

EXTENSIVE CLINICAL DATA DEMONSTRATED REDUCTION IN HYPERTENSION

The Symplicity™ and Symplicity Spyr™ renal denervation systems are backed by more than 11,000 patient-years of follow-up, >6,000 completed procedures and three years of real-world registry results.¹

For more detailed clinical evidence, visit SpyralStudy.com.



PROVEN TO REDUCE BLOOD PRESSURE

RDN lowered blood pressure in two randomized sham-controlled trials with and without medications

SPYRAL HTN-ON MED²

Change from baseline to 6 months

24-hour SBP	p=0.005	24-hour DBP	p=0.029
-9.0 mmHg	-1.6 mmHg	-6.0 mmHg	-1.9 mmHg
n=36 RDN	n=36 Sham	n=36 RDN	n=36 Sham

SPYRAL HTN-OFF MED³

Change from baseline to 3 months

24-hour SBP	p=0.041	24-hour DBP	p=0.002
-5.5 mmHg	-0.5 mmHg	-4.8 mmHg	-0.4 mmHg
n=35 RDN	n=36 Sham	n=35 RDN	n=36 Sham





BENEFITS ARE "ALWAYS ON"

Reduces blood pressure 24 hours a day, including high-risk times

SPYRAL HTN-ON MED DATA – 6 MONTHS²

Change from Baseline to 6 Months



W = Wake time reported by patients. For example, if W is 7 a.m., then W-4 is 3 a.m. and W+4 is 11 a.m.

EXCELLENT SAFETY PROFILE

- No major adverse events through 6 months in the SPYRAL HTN-ON MED or SPYRAL HTN-OFF MED trials^{2,3}
- Procedural and long-term safety through 3 years in real clinical practice^{4,5}
- Does not affect kidney function^{4,5}





UNPARALLELED REAL-WORLD RESULTS THROUGH 3 YEARS⁵

- Proven safety and efficacy in a variety of patients representative of daily clinical practice
- The Global Symplicity Registry (GSR) is the largest RDN data set with over 2,700 patients enrolled
- Longest follow-up of patients receiving RDN: data through 3 years

All Patients

-16.5 mmHg
n=1,183
Office

-8.9 mmHg
n=500
24-Hr ABPM

Resistant HTN^A

-23.5 mmHg
n=837
Office

-10.4 mmHg
n=302
24-Hr ABPM

ISH

-15.9 mmHg
n=477
Office

-8.6 mmHg
n=199
24-Hr ABPM

Diabetes

-16.4 mmHg
n=465
Office

-10.2 mmHg
n=201
24-Hr ABPM

CKD^B

-11.6 mmHg
n=254
Office

-10.1 mmHg
n=116
24-Hr ABPM

Atrial Fibrillation

-17.6 mmHg
n=144
Office

-10.0 mmHg
n=70
24-Hr ABPM

Chart details systolic blood pressure readings

^AResistant hypertension defined as OSBP > 150 mmHg, ≥3 anti-hypertensive medications

^BChronic Kidney Disease define as eGFR <60ml/min/1.73m²

REFERENCES

- Medtronic data on file.
- Kandzari DE, et al. *Lancet*. 2018;391:2346–2355.
- Townsend RR, et al. *Lancet*. 2017;390:2160–2170.
- Mahfoud F, et al. Presented at EuroPCR. 2018.
- Mahfoud F, et al. Presented at EuroPCR. 2019.
- Symplicity HTN-1 Investigators. *Hypertension*. 2011;57:911–917.
- Symplicity HTN-2 Investigators. *Lancet*. 2010;376:1903–1909.
- Bhatt DL, et al. *N Engl J Med*. 2014;370:1393–1401.

Europe

Medtronic Intl. Trading SARL

Route du Molliau 31
Case Postale
CH-1131 Tolochenaz
Switzerland
Tel: 41.21.802.7000
Fax: 41.21.802.7900

Asia Pacific

Medtronic Intl. Ltd.

49 Changi South Avenue 2
Nasaco Tech Centre
Singapore 486056
Singapore
Tel: 65.6436.5000
Fax: 65.6776.6335


Latin America

Medtronic USA, Inc.


Doral Corporate Center II
3750 NW 87th Avenue, Suite 700
Miami, FL 33178
USA
Tel: 305.500.9328
Fax: 786.709.4244

COMPREHENSIVE CLINICAL PROGRAM^{2,3,4,6,7,8}


Foundational Trials



Proof of Concept Trials



Prospectively Powered



Global Symplicity Registry – Up to 3,000 patients
Safety and Efficacy in Real-World Patients

©2019 Medtronic. All rights reserved. Medtronic, Medtronic logo, and Further, Together are trademarks of Medtronic. All other brands are trademarks of a Medtronic company. Not for distribution in the USA, Japan, or France. UC201910730 ML 05/2019

Medtronic
Further, Together